Pain Therapeutics, Durect Fall as Pfizer Evaluates Pill

Pain Therapeutics Inc. plunged 50 percent in its biggest drop ever after Pfizer Inc. said it was reassessing their partnership on the experimental painkiller Remoxy. A third partner, Durect Corp., also fell.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.